查詢結果分析
相關文獻
- Chemotherapy Combination with Bevacizumab for the Treatment of Vascular Sarcoma
- The Advantage of Bevacizumab in Treating Colorectal Brain Metastasis
- Primary Pleural Epithelioid Angiosarcoma Presenting with Persistent Pleural Effusion and Bone Metastases
- 肺血管肉瘤
- Angiosarcoma--Experience at Taipei Veterans General Hospital
- Successful Treatment of a Bulky Seminoma in an Abdominal Undescended Testis: A Case Report
- Ifosfamide-Based Chemotherapy for Previously Treated Lung Cancer Patients
- Cutaneous Epithelioid Angiosarcoma
- Treatment of Ultra-High Risk Gestational Trophoblastic Disease by an EMA/CE Regimen
- Hemoperitoneum Secondary to Biopsy of the Hepatic Angiosarcoma
頁籤選單縮合
題名 | Chemotherapy Combination with Bevacizumab for the Treatment of Vascular Sarcoma=化學治療併用Bevacizumab於血管性肉瘤 |
---|---|
作者 | 鄭弘毅; 蘇迺文; 陳功深; 張明志; 謝瑞坤; | 書刊名 | 臺灣癌症醫學雜誌 |
卷期 | 29:4 2013.12[民102.12] |
頁次 | 頁190-195 |
分類號 | 418.31 |
關鍵詞 | 血管肉瘤; 表皮血管肉瘤; 癌思停; 化學治療; Vascular sarcoma; Angiosarcoma; Hemangiopericytoma; Epithelioid hemangioendothelioma; Bevacizumab; Chemotherapy; |
語文 | 英文(English) |
中文摘要 | 血管性肉瘤是一種罕見的惡性腫瘤,往往因快速進展至轉移病灶,而死亡率相當高。 也因此治療方面以高度複雜的手術,放射治療,化學治療的合併治療為主。然而,預後 依然不佳。血管新生抑制劑,bevacizumab,因具有抑制血管新生的顯著效果,已經在各 類癌症如大腸癌、肺癌、乳癌被應用。在此我們提出四則病例使用 bevacizumab 為主的化 療處方來治療血管性肉瘤,其中一例得到部分緩解,二例為病情穩定,一例惡化,並做 文獻回顧及探討。 |
英文摘要 | Vascular sarcoma is a rare tumor associated with high mortality because of rapid local relapse and a high incidence of metastasis. A combination of surgery, radiotherapy and chemotherapy is commonly suggested, but this gives formidable insult to the patient, and yet, the prognosis remains poor. The angiogenesis inhibitor bevacizumab has been shown to have significant antitumor activity when used to treat various cancers and it is proposed that this is due, at least in part, to its anti-angiogenic effect. Here we present four cases of vascular sarcoma that treated with bevacizumab plus chemotherapy and retrospective review. The results are partial response in one case, stable disease in two cases, and disease progression in one case. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。